

# Contents

Preface .....	vii
Contributors .....	xvii

## Part One Carcinogenesis

1 The History of Mesothelioma .....	3
<i>Dorsett D. Smith</i>	
2 Asbestos-Induced Mesothelioma .....	21
<i>Maria E. Ramos-Nino, Marcella Martinelli, Luca Scapoli, and Brooke T. Mossman</i>	
3 SV40-Mediated Oncogenesis .....	34
<i>Maurizio Bocchetta and Michele Carbone</i>	
4 Mesothelioma Carcinogenesis: <i>In vivo</i> Models .....	60
<i>Umberto Saffiotti</i>	
5 Mesothelial and Mesothelioma Cell Lines .....	87
<i>Agnes B. Kane</i>	

## Part Two Molecular Genetics

6 Cytogenetics of Malignant Mesothelioma .....	101
<i>Sinoula Apostolou, Binaifer R. Balsara, and Joseph R. Testa</i>	
7 Growth Factors and Malignant Mesothelioma .....	112
<i>Paola Cacciotti, Luciano Mutti, and Giovanni Gaudino</i>	
8 Oncogenes and Tumor Suppressor Genes in Malignant Mesothelioma .....	124
<i>Robert A. Kratzke and Adi F. Gazdar</i>	

9	Angiogenesis and Mesothelioma . . . . .	141
	<i>Alfonso Catalano, Luigi Strizzi, and Antonio Procopio</i>	
10	Immune Status and Mesothelioma . . . . .	151
	<i>Elliott Kagan</i>	
11	Extracellular Matrix and Mesothelioma: Some Clues to the Invasive Behavior of Mesothelioma . . . . .	166
	<i>Julius Klominek and Dan Hauzenberger</i>	
12	Genomics and Proteomics in Mesothelioma . . . . .	186
	<i>Anil Wali and Harvey I. Pass</i>	
 <b>Part Three Epidemiology</b>		
13	Asbestos Mineralogy and Health Effects . . . . .	209
	<i>Meral Dogan and A. Umran Dogan</i>	
14	Molecular Epidemiology of Mesothelioma . . . . .	225
	<i>Riccardo Puntoni, Paolo G. Cerrano, and Rosangela Filiberti</i>	
15	Malignant Mesothelioma and Erionite . . . . .	242
	<i>A. Umran Dogan</i>	
16	Determination of Asbestos Exposure by Pathology and Clinical History . . . . .	259
	<i>Allen R. Gibbs</i>	
17	Mesothelioma and Asbestos Exposure . . . . .	267
	<i>J. Corbett McDonald and Alison McDonald</i>	
18	From Monkey to Man: The Epidemiologic Evidence of an Association Between Simian Virus 40 and Malignancy . . . . .	293
	<i>Susan Gross Fisher</i>	
19	Causes and Prevention of Technical Artifacts When Studying Simian Virus 40 (SV40) in Human Mesotheliomas . . . . .	309
	<i>Marc Ramael</i>	
20	Molecular Detection of Simian Virus 40 in Human Mesothelioma . . . . .	330
	<i>Bharat Jasani and Katie Ross</i>	
21	Malignant Mesothelioma Following Radiation . . . . .	350
	<i>Katherine DeCastro, Alfred I. Neugut, and Karen H. Antman</i>	

22	Genetics and Human Mesothelioma . . . . .	364
	<i>Michele Carbone and Izzetin Y. Baris</i>	

**Part Four Clinical Presentation**

23	Clinicians' Approach to Mesothelioma . . . . .	369
	<i>Philip Harber and J. Bernard L. Gee</i>	
24	Clinical Presentation and Natural History of Mesothelioma: Pleural and Pericardial . . . . .	380
	<i>A. Philippe Chahinian</i>	
25	Clinical Presentation and Natural History of Mesothelioma: Abdominal . . . . .	391
	<i>Claire F. Verschraegen, Charles R. Key, and Raffit Hassan</i>	
26	Staging of Mesothelioma . . . . .	402
	<i>Raja M. Flores and Valerie W. Rusch</i>	
27	Prognostic Factors in Mesothelioma . . . . .	416
	<i>Jeremy P.C. Steele and Dean A. Fennell</i>	

**Part Five Imaging and Endoscopy**

28	Radiologic Assessment of Mesothelioma . . . . .	433
	<i>Samuel G. Armato III, Heber MacMahon, Geoffrey R. Oxnard, Charles L. Croteau, and Nicholas J. Vogelzang</i>	
29	Endoscopic Imaging . . . . .	454
	<i>Gian Franco Tassi and Gian Pietro Marchetti</i>	

**Part Six Pathology**

30	Benign Mesotheliomas, Mesothelial Proliferations, and Their Possible Association with Asbestos Exposure . . . . .	469
	<i>Giovan Giacomo Giordano and Oscar Nappi</i>	
31	Cytology of Malignant Mesothelioma . . . . .	481
	<i>Richard M. DeMay</i>	
32	Immunohistochemistry . . . . .	490
	<i>Betta Pier-Giacomo</i>	

33	Malignant Mesothelioma Electron Microscopy . . . . .	508
	<i>Raoul Fresco</i>	
34	Rare Variants of Mesothelioma . . . . .	517
	<i>Markku Miettinen</i>	
35	Differentiating Sarcomas from Mesotheliomas . . . . .	527
	<i>Oliver Kim and Thomas Krausz</i>	
36	Diagnosis of Synovial Sarcoma of the Pleura and Differentiation from Malignant Mesothelioma . . . . .	543
	<i>Amy Powers and Michele Carbone</i>	
37	Pitfalls in the Diagnosis of Malignant Mesothelioma . . . . .	555
	<i>Donald G. Guine, Jr. and William D. Travis</i>	

**Part Seven Treatment**

38	Management of Benign Variants of Mesothelioma . . . . .	581
	<i>Raja M. Flores</i>	
39	First-Line Chemotherapy for Malignant Pleural Mesothelioma . . . . .	593
	<i>Pasi A. Jänne</i>	
40	Second-Line Chemotherapy . . . . .	607
	<i>N. Pavlakis and Nicholas J. Vogelzang</i>	
41	Treatment of Mesothelioma with Radiotherapy . . . . .	616
	<i>Ryan P. Smith and Stephen M. Hahn</i>	

**Part Eight Multimodality Approaches**

42	Intrapleural Chemotherapy with and Without Surgery in Malignant Pleural Mesothelioma (MPM) . . . . .	631
	<i>Bilal Piperdi, Dong M. Shin, and Roman Perez-Soler</i>	
43	Management of Pleural Effusions in Mesothelioma . . . . .	638
	<i>Shahriyoor Andaz and Robert B. Cameron</i>	
44	Preoperative Chemotherapy and Surgery . . . . .	657
	<i>Eric Vallières</i>	
45	Photodynamic Therapy for Pleural Mesothelioma . . . . .	667
	<i>Evelio Rodriguez, Paul Baas, and Joseph Friedberg</i>	
46	Surgery and Postoperative Radiotherapy . . . . .	678
	<i>Raja M. Flores, Kenneth E. Rosenzweig, and Valerie W. Rusch</i>	

47 The Development of the Brigham and Women’s  
Multimodality Treatment Plan for Malignant Pleural  
Mesothelioma: A Model for Improving the Treatment  
of Rare Diseases . . . . . 696  
*Michael T. Jaklitsch, Daniel Wiener, Raphael Bueno, and  
David J. Sugarbaker*

48 Peritoneal Mesothelioma: The Columbia Experience . . . . . 723  
*Jennifer A. Wagmiller, Mary-Louise Keohan, John A. Chabot,  
Karen Fountain, Mary Hesdorffer, and Robert N. Taub*

49 Surgery, Hyperthermic Chemoperfusion, and  
Postoperative Chemotherapy: The National Cancer  
Institute and Washington Hospital Center Experience . . . . . 732  
*Nancy M. Carroll, Faheez Mohamed, Paul H. Sugarbaker,  
and H. Richard Alexander*

50 Pericardial and Tunica Vaginalis Mesothelioma . . . . . 755  
*Bruno Pasquotti*

**Part Nine Novel Treatment Strategies**

51 New Target Therapies for Malignant Mesothelioma . . . . . 765  
*Camillo Porta and Luciano Mutti*

52 Gene Therapy for Malignant Pleural Mesothelioma . . . . . 778  
*Steven M. Albelda, Larry R. Kaiser, and Daniel H. Serman*

53 Immunotherapeutic Approaches and  
Vaccination Strategies . . . . . 798  
*Anna K. Nowak, Richard A. Lake, and Bruce W.S. Robinson*

**Part Ten Economic Implications**

54 Economic Aspects of Mesothelioma . . . . . 821  
*Joyce A. Lagnese*

Index . . . . . 833